Opiant Pharmaceuticals says Narcan surpassed $25M of net sales in 1H17
Opiant Pharmaceuticals provided an update on Narcan Nasal Spray. Recent highlights of the Narcan Nasal Spray include: Surpassing $25 million of net sales for the first half of calendar 2017, triggering SWK Funding LLC's obligation to pay Opiant an additional $3.75 million; Mandatory co-prescribing of naloxone to patients receiving opioid prescriptions, who are considered at high risk of opioid overdose, in Virginia and Vermont; Recommended co-prescribing of naloxone with opioid painkillers by both the Centers for Disease Control and The Veterans Administration; In over 40 states, Narcan Nasal Spray can now be purchased from pharmacies without a prescription; Adapt has maintained the price of Narcan Nasal Spray, including a discounted public interest price of $75 per two-dose pack. Opiant is developing other products for Opioid Use Disorder, including advancing the pre-clinical development of its heroin vaccine candidate, which was licensed in October 2016 from the Walter Reed Army Institute of Research and the National Institute on Drug Abuse. Opiant continues to maintain an active presence in national organizations such as the National Institutes of Health, where Dr. Crystal was recently invited to advise on the development of medications for Opioid Use Disorder.